Showing 1631-1640 of 5771 results for "".
- Ocular Therapeutix To Present Data at the American Academy of Ophthalmology (AAO) 2022 Annual Meetinghttps://modernod.com/news/ocular-therapeutix-to-present-data-at-the-american-academy-of-ophthalmology-aao-2022-annual-meeting/2481110/Ocular Therapeutix announced multiple presentations at the American Academy of Ophthalmology (AAO) 2022 Annual Meeting being held September 30-October 3, 2022 at McCormick Place Convention Center in Chicago. “We have a big presence at AAO this year with many presentations dis
- Thea Pharma Announces Activities and Events at the Upcoming American Academy of Ophthalmology (AAO) Annual Meetinghttps://modernod.com/news/thea-pharma-announces-activities-and-events-at-the-upcoming-american-academy-of-ophthalmology-aao-annual-meeting/2481108/Thea Pharma announced that the company will attend and participate in a number of meetings and events taking place at or in association with the American Academy of Ophthalmology Meeting, being held Sept. 30 to Oct. 3 at McCormick Place in Chicago. Thea will exhibit its flagship product
- Atsena Therapeutics Announces Late-Breaker Presentation at the AAO Annual Meetinghttps://modernod.com/news/atsena-therapeutics-announces-late-breaker-presentation-at-the-aao-annual-meeting/2481107/Atsena Therapeutics announced that data from the phase 1/2 clinical trial of ATSN-101 will be presented in a late breaking developments session during the Retina Subspecialty Day at the American Academy of Ophthalmology Annual Meeting (AAO 2022), which is being held Sept
- Alimera Announces Reimbursement of Uveitis Indication Granted for Iluvien in Irelandhttps://modernod.com/news/alimera-announces-reimbursement-of-uveitis-indication-granted-for-iluvien-in-ireland/2481105/Alimera Sciences announced that Alimera Sciences Europe, its Ireland-based European subsidiary, has been granted reimbursement for Iluvien (fluocinolone acetonide intravitreal implant) 0.19 mg sustained release intravitreal implant for noninfectious uveitis affecting the posterior segme
- Nicox Announces Last Patients Complete Final Visit in NCX 470 Phase 3 Mont Blanc Glaucoma Trialhttps://modernod.com/news/nicox-announces-last-patients-complete-final-visit-in-ncx-470-phase-3-mont-blanc-glaucoma-trial/2481100/Nicox announced that the last patients completed their final (3-month) visit in the Mont Blanc phase 3 clinical trial of NCX 470 0.1% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension. A total of
- Adverum Biotechnologies Announces First Subject Dosed with Ixo-vec in the Phase 2 LUNA Trial for the Treatment of Wet AMDhttps://modernod.com/news/adverum-biotechnologies-announces-first-subject-dosed-with-ixo-vec-in-the-phase-2-luna-trial-for-the-treatment-of-wet-amd/2481097/Adverum Biotechnologies announced that the first subject was dosed in the LUNA phase 2 trial evaluating ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022) for the treatment of wet (AMD). “Dosing the first subject in the phase 2 LUNA study brings us a step cl
- BVI Announces Certification for its IOL Portfolio Under the European Medical Device Regulationhttps://modernod.com/news/bvi-announces-certification-for-its-iol-portfolio-under-the-european-medical-device-regulation/2481094/BVI announced certification for its IOL portfolio under the European Medical Device Regulation (MDR, (EU) 2017/745) from its Notified Body, the British Standards Institution (BSI)¹. The new regulatory criteria came into effect in May 2021, replacing the prior Medica
- Glaukos Announces Positive Topline Outcomes in Two Phase 3 Pivotal Trials of iDose TRhttps://modernod.com/news/glaukos-announces-positive-topline-outcomes-for-both-phase-3-pivotal-trials-of-idose-tr/2481092/Glaukos announced positive topline data for both phase 3 pivotal trials of iDose TR that successfully achieved its prespecified primary efficacy endpoints through 3 months in both phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 1
- Nanoscope Announces Completion of Enrollment in STARLIGHT Phase 2 Trial of MCO-010 Optogenetic Gene Therapy for Stargardt Diseasehttps://modernod.com/news/nanoscope-therapeutics-announces-completion-of-enrollment-in-starlight-phase-2-clinical-trial-of-mco-010-optogenetic-gene-therapy-for-stargardt-disease/2481089/Nanoscope Therapeutics announced full enrollment of its phase 2 clinical trial of MCO-010, an ambient-light activatable Multi-Characteristic Opsin (MCO) optogenetic monotherapy to restore vision in blind patients, for Stargardt disease. Six-month data from the phase 2 STARLIGHT trial are exp
- Sight Sciences Announces Completion of Enrollment in SAHARA, a Randomized Clinical Trial of the TearCare System vs Restasishttps://modernod.com/news/sight-sciences-announces-completion-of-enrollment-in-sahara-a-randomized-clinical-trial-of-the-tearcare-system-vs-restasis/2481086/Sight Sciences announced the completion of enrollment in the SAHARA trial, a study designed to evaluate whether an interventional dry eye procedure with the TearCare System is superior in alleviating the signs and symptoms of dry eye disease compared to 6-months of twice daily Restasis&